EDB

Introducing Findability.Accelerate: Expediting the Journey from Data Silos to AI-Readiness

Retrieved on: 
Wednesday, September 21, 2022
Data, ROI, NPS, Adoption, Gaps, EDB, IIAS, Machine learning, Risk, Amazon Redshift, AWS, IA, Organization, DB2, Partnership, IP, PricewaterhouseCoopers, Netezza, SAP, Findability, Intelligence, Snowflake, Technology, CEO, Goal, Solution, KPI-driven code analysis, Architecture, Leadership, Record, Automation Anywhere, Research, Automation, Data science, AI, Net, Marketing, Medical device, Video game console, Customer service, Risk management

BOSTON, Sept. 21, 2022 /PRNewswire/ -- Findability Sciences, a global provider of enterprise AI solutions and an Inc. 5000 company, today announced the launch of Findability.Accelerate, which provides the tools and framework necessary to equip enterprises to become 'AI-ready' and expedite their AI journey. The demand for AI tech has surged in the post-pandemic world; PwC reported that AI is estimated to contribute up to $15.7 trillion to the global economy by 2030 and change the game by emphasizing productivity and consumption.

Key Points: 
  • Organizations require that data is cleaned, analyzed and organized, but too often, enterprises are struggling with data overload and crippling silos that can hinder digital transformation.
  • In addition, the platform also offers a customized comprehensive report to unify data for AI, as well as provides plugins for data migration and machine learning.
  • "With the skills, processes and technology that Findability.Accelerate offers, an organization can successfully optimize data and succeed in its AI journey," continues Mahurkar.
  • Findability.Accelerate addresses data gaps and silos with a Data Census designed to identify business processes, data sets, personally-identifiable information, third-party data and applications.

Juniper Biologics Establishes Global Headquarters in Singapore

Retrieved on: 
Thursday, September 15, 2022
Headquarters, Health, EDB, The Singapore Economic Review, Company, Acquisition, Degenerative disease, Patient, Economic Development Board, Quality of life, Science, Gene therapy, Hyundai, Sylvan, Pharmaceutical industry

SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations. This announcement was supported by the Singapore Economic Development Board (EDB) who congratulated Juniper Biologics on the significance of this milestone. Juniper Biologics is backed by The Sylvan Group, an independent private equity investment firm focused on deep value companies with strong ESG-compliance.

Key Points: 
  • SINGAPORE, Sept. 15, 2022 /PRNewswire/ --Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations.
  • The establishment of its headquarters in Singapore is part of Juniper Biologics' commitment to Singapore and the wider region and will go towards supporting the company'splan to build out a patient-centric presence throughout key markets in the region and around the globe.
  • "Juniper Biologics' decision to establish its global headquarters in Singapore affirms and reflects our position as a leading hub for pharmaceutical companies looking to drive and grow their businesses in the region.
  • "Singapore is an excellent hub for Juniper Biologics to base our global operations, giving us the combination of easy access with strong reach to support our goal of bringing the next generation of medicines to patients throughout the region and beyond," said Raman Singh, Chief Executive Officer of Juniper Biologics.

Juniper Biologics Establishes Global Headquarters in Singapore

Retrieved on: 
Thursday, September 15, 2022
Headquarters, Health, EDB, The Singapore Economic Review, Company, Acquisition, Degenerative disease, Patient, Economic Development Board, Quality of life, Science, Gene therapy, Hyundai, Sylvan, Pharmaceutical industry

SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations. This announcement was supported by the Singapore Economic Development Board (EDB) who congratulated Juniper Biologics on the significance of this milestone. Juniper Biologics is backed by The Sylvan Group, an independent private equity investment firm focused on deep value companies with strong ESG-compliance.

Key Points: 
  • SINGAPORE, Sept. 15, 2022 /PRNewswire/ --Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations.
  • The establishment of its headquarters in Singapore is part of Juniper Biologics' commitment to Singapore and the wider region and will go towards supporting the company'splan to build out a patient-centric presence throughout key markets in the region and around the globe.
  • "Juniper Biologics' decision to establish its global headquarters in Singapore affirms and reflects our position as a leading hub for pharmaceutical companies looking to drive and grow their businesses in the region.
  • "Singapore is an excellent hub for Juniper Biologics to base our global operations, giving us the combination of easy access with strong reach to support our goal of bringing the next generation of medicines to patients throughout the region and beyond," said Raman Singh, Chief Executive Officer of Juniper Biologics.

EDB Chief Executive Officer Ed Boyajian Named Chairman of the Board

Retrieved on: 
Tuesday, August 30, 2022
Professional Services, Data Management, Other Professional Services, Technology, Software, Finance, Networks, EDB, Technology, View, Government, Linux, Board, Â, Information technology, Organization, Database, Leadership, EnterpriseDB, Board of directors, Association, Director, Acquisition, Growth, Industry, Management, PostgreSQL

EnterpriseDB (EDB), the leader in accelerating Postgres in the enterprise, today announced that President and Chief Executive Officer Ed Boyajian has been named Chairman of the Board of Directors.

Key Points: 
  • EnterpriseDB (EDB), the leader in accelerating Postgres in the enterprise, today announced that President and Chief Executive Officer Ed Boyajian has been named Chairman of the Board of Directors.
  • Mr. Boyajian is an open source pioneer who has led EDB since 2008 and driven the companys vision and growth globally.
  • His selection as Chairman of the Board reflects EDBs transformative capabilities, success and momentum under his leadership, the companys strong position in Postgres, and the database market overall.
  • Among his many accomplishments are the following:
    Brought together two of the leading private equity firms to invest in EDB and Postgres.

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update

Retrieved on: 
Monday, August 15, 2022
Diamond, FDA, ADC, IO, IND World's Fair Line, Risk, GLP, Private Securities Litigation Reform Act, Industry, Sorafenib, GLOBE, EDB, Black Diamond, Population, Drug, Squamous cell carcinoma, Growth, SEC, Cancer, PD-1, Board, Research, NSCLC, Quality of life, Patient, Review, Company, Bristol Myers Squibb, Large-cell lung carcinoma, Breast cancer, Therapy, Drug development, Control, Bayer, Board of directors, Insurance, Nasdaq, Escape Room, Ipilimumab, Common stock, DLK1, Investigational New Drug, Pharmaceutical industry, Fine chemical, Online gambling, Director

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a diversified oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients, today reported financial results for the second quarter and six months ended June 30, 2022 and provided a corporate update.

Key Points: 
  • Focus on advancing lead programs toward the clinic with near-term catalysts: Pyxis Oncology is on track to file Investigational New Drug applications (INDs) for PYX-201 and PYX-106 in 2022.
  • Pausing development of anti-CD123 ADC, PYX-203, and anti-KLRG1 IO program, PYX-102: The Company will pause the preclinical development of PYX-203 and PYX-102.
  • As of August 15, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,834,561.
  • Pyxis Oncology, Inc. is an oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients.

New Excess Deposit Bond Policies from Parr Insurance Provide Protection Beyond FDIC Limits

Retrieved on: 
Tuesday, August 2, 2022
FDIC, Government, EBD, EDB, Compliance, Review, Insurance, Federal Deposit Insurance Corporation, Melissa, Parr, Bank, Neis

CHICAGO, Aug. 2, 2022 /PRNewswire/ -- Financial institutions and large depositors – such as municipalities, school districts, government agencies and high-net-worth individuals – will benefit from the Excess Deposit Insurance Bond (EDB) now offered by Chicago-based Parr Insurance Brokerage that guarantees cash holdings in excess of the Federal Deposit Insurance Corp. (FDIC) $250,000 limit.

Key Points: 
  • CHICAGO, Aug. 2, 2022 /PRNewswire/ -- Financial institutions and large depositors such as municipalities, school districts, government agencies and high-net-worth individuals will benefit from the Excess Deposit Insurance Bond (EDB) now offered by Chicago-based Parr Insurance Brokerage that guarantees cash holdings in excess of the Federal Deposit Insurance Corp. (FDIC) $250,000 limit.
  • EDB features an easy approval process; premiums based on limits used, not on limits available; and, with its competitive rates, is more cost effective than alternative solutions.
  • Chicago-based Parr Insurance Brokerage provides best-in-class, customized insurance coverage for financial institutions, high-net-worth individuals, business owners, property managers and more.
  • Parr Insurance provides coverage for high-value homes, professional exposures, valuable possessions and collections and coverage in response to the rapidly growing sharing economy.

DayDayCook and Brinc commit to investing in 45 food tech companies that impact global food sustainability goals through the Good Food Accelerator Program

Retrieved on: 
Thursday, July 21, 2022
Tamkeen, RTH, Functional, Partnership, Multimedia, Robotics, Huawei, GFI, IOT, Green, Goal, Manulife, Food Tech, National university, Climate change, Meat, Merck, Acceleration, DDC, Program, Growth, Nestlé, Mainland, Sequoia Capital, IPO, Industry, National University of Singapore, CEO, Batelco, Puma, Agricultural technology, APAC, Food technology, Pharmacy, RTC, Food, EDB, Time, Good Food, Food security, Social media, Artificial intelligence, Guangdong-Hong Kong-Macau Greater Bay Area, Adoption, LP record, Schneider Electric, Internet of things, Renewable energy, Agriculture, Pharmaceutical industry, Omantel, Galy Records, Artesian, Greater China, Alchemy

DayDayCook and Brinc join forces to invest US$10 million over the next three years through the Good Food Accelerator Program.

Key Points: 
  • DayDayCook and Brinc join forces to invest US$10 million over the next three years through the Good Food Accelerator Program.
  • DayDayCook and Brinc share a dedicated mission to tackle global food sustainability goals by developing sustainable food systems and addressing food security issues in China and Asia.
  • DayDayCook and Brinc will invest in and support 45 companies over the next three years through the Good Food Accelerator Program, operated by Brinc.
  • Companies with commercial-ready products and services that are actively contributing toward global food sustainability goals will be prioritised.

DayDayCook and Brinc commit to investing in 45 food tech companies that impact global food sustainability goals through the Good Food Accelerator Program

Retrieved on: 
Thursday, July 21, 2022
Tamkeen, RTH, Functional, Partnership, Robotics, Huawei, GFI, IOT, Green, Goal, Manulife, Food Tech, National university, Climate change, Meat, Merck, Acceleration, DDC, Program, Growth, Nestlé, Mainland, Sequoia Capital, IPO, Industry, National University of Singapore, CEO, Batelco, Puma, Agricultural technology, APAC, Food technology, Pharmacy, RTC, Food, EDB, Time, Good Food, Food security, Social media, Artificial intelligence, Guangdong-Hong Kong-Macau Greater Bay Area, Adoption, LP record, Schneider Electric, Internet of things, Renewable energy, Agriculture, Pharmaceutical industry, Omantel, Galy Records, Artesian, Greater China, Alchemy

DayDayCook and Brinc join forces to invest US$10 million over the next three years through the Good Food Accelerator Program.

Key Points: 
  • DayDayCook and Brinc join forces to invest US$10 million over the next three years through the Good Food Accelerator Program.
  • DayDayCook and Brinc share a dedicated mission to tackle global food sustainability goals by developing sustainable food systems and addressing food security issues in China and Asia.
  • DayDayCook and Brinc will invest in and support 45 companies over the next three years through the Good Food Accelerator Program, operated by Brinc.
  • Companies with commercial-ready products and services that are actively contributing toward global food sustainability goals will be prioritised.

WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation

Retrieved on: 
Tuesday, July 19, 2022
Ecosystem, CEO, Disease, Patient, Solution, Wuxi, MSCI, AA, EDB, Development, Contract research organization, Health, The Singapore Economic Review, Fine chemical

SINGAPORE, July 19, 2022 /PRNewswire/ --WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site in Singapore.

Key Points: 
  • SINGAPORE, July 19, 2022 /PRNewswire/ --WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site in Singapore.
  • The company intends to invest up to S$2 billion (approximately US$1.43 billion) to construct and operationalize the site, which aims to further enable global partners to advance healthcare innovations.
  • The investment is expected to be made in stages over the next 10 years, depending on the company's business needs.
  • "We warmly welcome WuXi AppTec's plan," said Dr. Beh Swan Gin, Chairman of the Singapore Economic Development Board (EDB).

Five New Members Join the Data on Kubernetes Community to Advance the Use of Kubernetes for Data

Retrieved on: 
Monday, July 11, 2022
Software, Technology, Data Management, DataStax, Solution, AWS, Adobe, Software, Pure Storage, AI, EDB, DOK, TommyInnit, Apache Kafka, DevOps, Apache, Data, Software as a service, NSA ANT catalog, DataCore, PostgreSQL, Database, Organization, Mobile phone, Container crane, Kubernetes, Time scale, Twilio

The Data on Kubernetes Community (DoKC) today announced five new members covering extensive expertise and customers in Kubernetes management, data protection, and measurement sectors.

Key Points: 
  • The Data on Kubernetes Community (DoKC) today announced five new members covering extensive expertise and customers in Kubernetes management, data protection, and measurement sectors.
  • DoKC is an openly governed group of practitioners collaborating to accelerate the use of Kubernetes for data.
  • The recently launched DoK Landscape documents existing products, solutions, and consultancies that enable data on Kubernetes including database, storage, data manager software, and operators themselves.
  • The indicators are clear: organizations want to run data workloads on Kubernetes and are in search of more robust solutions to the data challenges.